Abstract Library

#4289 Temozolomide-associated hypermutation and response to immunotherapy in advanced pulmonary neuroendocrine tumours

Introduction: Temozolomide (TMZ) cytotoxicity depends on an intact DNA mismatch repair (MMR) pathway and low levels of O6-methylguanine DNA methyltransferase (MGMT). However, absence of MGMT-mediated repair coupled with defective MMR (dMMR) may lead to enrichment of C:G to A:T transitions throughout the genome, a marked increase in tumour mutational burden (TMB), and loss of TMZ-induced cytotoxicity. This resistance mechanism is called TMZ-associated hypermutation (TAH). Theoretically, this effect could lead to sensitivity to checkpoint inhibitor immunotherapy.

Conference:

Presenting Author: Buikhuisen W

Authors: Buikhuisen W, Badrising S, Moonen L, Derks J, Monkhorst K,

Keywords: Pulmonary NET, whole genome sequencing, temozolomide signature, immunotherapy,

#4204 Personalised dosimetry as a key for optimising radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE in patients with neuroendocrine tumors – The DUONEN multicenter study

Introduction: To date, there is no clear consensus on the optimal RLT regimen. In theory, simultaneous use of two radionuclides with different energy and radiation ranges should be more effective than monotherapy. Individually tailored dosimetry may improve the results of RLT while maintaining its safety.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Kaminski G, Dedecjus M, Kowalska A, Kolodziej M,

Keywords: PRRT, RLT, personalized RTL, NET, Dosimetry,

#3763 Comparable survival benefit of surgical approaches for small grade 1 pancreatic neuroendocrine tumors – A propensity score matching study

Introduction: Pancreatic neuroendocrine tumors (pNETs) are rare neuroendocrine tumors (NETs) for which little is known about their treatment option. The optimal surgical management for small grade 1 pNETs (G1 pNETs) is still a matter of debate.

Conference:

Presenting Author: Chen J

Authors: Chen J, Jiang Y, Chen Q, Deng Y, Zhao H,

Keywords: Pancreatic neuroendocrine tumor, Surgery, Prognosis, SEER,

#3675 Care trajectory, informational needs and challenges of patients with neuroendocrine tumors – A mixed methods study

Introduction: Patients with neuroendocrine tumors (NET) encounter different challenges, including delayed diagnosis and difficulty finding NET-specific information of high-quality.

Conference:

Presenting Author:

Authors: Bénard F, Mercier F, Huez S, Pomey M,

Keywords: neuroendocrine, cancer, needs, information, challenges,

#3221 Independent administration of long-acting somatostatin analogues (SSAs) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET): Potential savings of increased uptake in the UK National Health Service (NHS)

Introduction: Lanreotide Autogel (LAN) and octreotide long-acting release (OCT) are long-acting SSAs used to treat GEP-NET. Only LAN is approved for independent (self/partner) injection, obviating need for in-person provider visits. Uptake of this option, already convenient for some patients, has accelerated in the UK amid the COVID-19 pandemic, with delivery modes reorganized in line with “COVID-19 rapid guideline: delivery of systemic anticancer treatments [NG161]” published for the NHS.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Harrow B, Cristeau O, Clay E, Francois C, Frankcom I,

Keywords: somatostatin analogues, GEP-NET, HEOR, covid-19,